We’d love to hear your feedback on this activity. It helps us to continually improve our products.
We were delighted to speak with Prof. Erika Petersen (University of Arkansas for Medical Sciences, Little Rock, AR, USA) around the six month results from the SENZA-PDN study. The abstract entitled: ‘Sustained Benefits for 10 kHz Spinal Cord Stimulation Treatment of Painful Diabetic Neuropathy—Six Month Results from a Multicenter Randomized Controlled Trial’ was presented at […]
We were delighted to meet with Jeffery Guptill (Duke University Medical Center, Durham, NC, USA) to discuss the Vivacity-MG study results (NCT03772587), investigating nipocalimab as a treatment option for Myasthenia Gravis. The abstract entitled: ‘Vivacity-MG: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Nipocalimab […]
We were delighted to meet with Gregory Branigan (University of Arizona, AZ, USA) to discuss the impact of estrogen therapies on Alzheimer’s disease pathways. The abstract entitled: ‘Breast Cancer Therapies Reduce Risk of Alzheimer’s Disease and Dementia: Clinic to Bench Translation’ was presented at the American Academy of Neurology Virtual Annual Meeting 2021. Questions: What […]
TouchNEUROLOGY had the pleasure of meeting with Anthony (Tony) Traboulsee (University of British Columbia, Vancouver, Canada) to discuss the Phase 2b study investigating tolebrutinib in patients with highly active relapsing multiple sclerosis. The abstract entitled: ‘Efficacy and Safety of Tolebrutinib in Patients With Highly Active Relapsing MS: Subgroup Analysis of the Phase 2b Study’ was […]
We had the pleasure of meeting with Chia-Chun Chiang (Mayo Clinic, Rochester, MN, USA) to discuss a real world study of ubrogepant in participants with acute migraine. The abstract entitled: ‘Real World Efficacy, Tolerability and Safety of Ubrogepant’ was presented at the American Academy of Neurology Virtual Annual Meeting 2021. Questions: What is the current […]
We were delighted to meet with Messoud Ashina (University of Copenhagen, Copenhagen, Denmark) to discuss his study results, investigating atogepant as a treatment option for migraine. The abstract entitled: ‘Long-term Safety and Tolerability of Atogepant 60 mg Following Once Daily Dosing Over 1 Year for the Preventive Treatment of Migraine’ was presented at the American […]
We were delighted to meet with Messoud Ashina (University of Copenhagen, Copenhagen, Denmark) to discuss the long term safety and tolerability profile of atogepant, and its place as a preventative option for migraine. The abstract entitled: ‘Long-term Safety and Tolerability of Atogepant 60 mg Following Once Daily Dosing Over 1 Year for the Preventive Treatment […]
Dr Jiwon Oh (University of Toronto, Canada) caught up with touchNEUROLOGY to discuss investigating fenebrutinib as a potential Multiple Sclerosis therapy. The abstract entitled: ‘The Safety of Fenebrutinib in a Large Population of Patients With Diverse Autoimmune Indications Supports Investigation in Multiple Sclerosis (MS)’ was presented at the American Academy of Neurology Virtual Annual Meeting […]
It was a pleasure to meet with Jerry Mendell (Nationwide Children’s Hospital, Columbus, OH, USA) to discuss his recent work in the gene-delivery clinical trial of rAAVrh74.MHCK7.micro-dystrophin (SRP-9001) for Duchenne Muscular Dystrophy. The abstract entitled: ‘A Multicenter Randomized, Double-Blind, Placebo-Controlled, Gene-Delivery Clinical Trial of rAAVrh74.MHCK7.micro-dystrophin for Duchenne Muscular Dystrophy’ was presented at the American Academy […]
Get the latest clinical insights from touchNEUROLOGY